Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Blinded, Placebo-Controlled Study of MTIG7192A, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Naive Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Trial Profile

A Phase II, Randomized, Blinded, Placebo-Controlled Study of MTIG7192A, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Naive Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Tiragolumab (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms CITYSCAPE
  • Sponsors Genentech
  • Most Recent Events

    • 19 Jun 2020 Planned End Date changed from 31 Oct 2020 to 31 Jan 2022.
    • 31 May 2020 Results of primary analysis (at 30 June 2019) assessing efficacy and safety presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 28 May 2020 According to a Sarah Cannon media release, Dr. Johnson will present primary analysis from this study in oral presentation (Abstract 9503) at the American Society of Clinical Oncology's (ASCO) Annual Meeting being held virtually May 29 -31, 2020.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top